Radiodermatitis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Radiodermatitis - Pipeline Review, H2 2018’, provides an overview of the Radiodermatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiodermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Radiodermatitis

- The report reviews pipeline therapeutics for Radiodermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Radiodermatitis therapeutics and enlists all their major and minor projects

- The report assesses Radiodermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Radiodermatitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Radiodermatitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Radiodermatitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Daiichi Sankyo Co Ltd

Foresee Pharmaceuticals Co Ltd

Matrix Biomed Inc

SK Chemicals Co Ltd

Sunny Pharmtech Inc

Daiichi Sankyo Co Ltd

Foresee Pharmaceuticals Co Ltd

Matrix Biomed Inc

SK Chemicals Co Ltd

Sunny Pharmtech Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Radiodermatitis - Overview 5

Radiodermatitis - Therapeutics Development 6

Radiodermatitis - Therapeutics Assessment 12

Radiodermatitis - Companies Involved in Therapeutics ...

Table of Contents

Table of Contents 2

Introduction 4

Radiodermatitis - Overview 5

Radiodermatitis - Therapeutics Development 6

Radiodermatitis - Therapeutics Assessment 12

Radiodermatitis - Companies Involved in Therapeutics Development 19

Radiodermatitis - Drug Profiles 22

Radiodermatitis - Dormant Projects 32

Radiodermatitis - Discontinued Products 33

Appendix 34

List of Tables

List of Tables

Number of Products under Development for Radiodermatitis, H2 2018 7

Number of Products under Development by Companies, H2 2018 9

Number of ...

List of Tables

Number of Products under Development for Radiodermatitis, H2 2018 7

Number of Products under Development by Companies, H2 2018 9

Number of Products under Development by Universities/Institutes, H2 2018 10

Products under Development by Companies, H2 2018 11

Products under Development by Universities/Institutes, H2 2018 12

Number of Products by Stage and Target, H2 2018 14

Number of Products by Stage and Mechanism of Action, H2 2018 16

Number of Products by Stage and Route of Administration, H2 2018 18

Number of Products by Stage and Molecule Type, H2 2018 19

Radiodermatitis - Pipeline by Daiichi Sankyo Co Ltd, H2 2018 20

Radiodermatitis - Pipeline by Foresee Pharmaceuticals Co Ltd, H2 2018 20

Radiodermatitis - Pipeline by Matrix Biomed Inc, H2 2018 21

Radiodermatitis - Pipeline by SK Chemicals Co Ltd, H2 2018 21

Radiodermatitis - Pipeline by Sunny Pharmtech Inc, H2 2018 22

Radiodermatitis - Dormant Projects, H2 2018 33

Radiodermatitis - Discontinued Products, H2 2018 34

List of Figures

List of Figures

Number of Products under Development for Radiodermatitis, H2 2018 7

Number of Products under Development by Companies, H2 2018 8

Number of ...

List of Figures

Number of Products under Development for Radiodermatitis, H2 2018 7

Number of Products under Development by Companies, H2 2018 8

Number of Products by Targets, H2 2018 13

Number of Products by Stage and Targets, H2 2018 13

Number of Products by Mechanism of Actions, H2 2018 15

Number of Products by Stage and Mechanism of Actions, H2 2018 15

Number of Products by Routes of Administration, H2 2018 17

Number of Products by Stage and Routes of Administration, H2 2018 17

Number of Products by Stage and Molecule Types, H2 2018 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports